The India Cements (INDIACEM) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
6 Jan, 2026Executive summary
Cement demand remained steady, supported by increased government CapEx, with 2,108 km of highways built in Q1 FY26, up 8.9% year-over-year.
Sales volume grew between 9.7% and 11.6% year-over-year in Q1 FY26, with India Cements and Kesoram integration progressing well.
Urban housing showed signs of a future rebound, while rural markets continued to perform well.
Cement realizations (net of logistics) improved up to 5.7% quarter-over-quarter.
EBITDA per ton rose to ₹424 from ₹88 in Q4 FY25, and average interest rate declined to 6.83%.
Financial highlights
Net sales for Q1 FY26 were about ₹1,025 crore, nearly flat year-over-year.
Consolidated PBIDT/EBITDA improved to ₹92 crore from a loss of ₹9 crore in Q1 FY25.
PAT before exceptions was a loss of ₹241 crore, with reported PAT loss at ₹133 crore.
Free cash flow to firm was negative at ₹81 crore for Q1 FY26.
Finance costs reduced sharply to ₹26.58 crores from ₹82.36 crores year-over-year due to debt refinancing.
Outlook and guidance
Double-digit volume growth targeted for FY26, supported by new capacities and integration of acquisitions.
CapEx for FY26 is close to INR 10,000 crores, with further guidance for FY27 to be provided later.
Planned capex for productivity and energy efficiency expected to yield benefits from Q4 FY27.
Green power (RE + WHRS) targeted to scale from 5% to 86% by FY27.
Profitability is expected to improve as capex benefits and synergies from the holding company materialize.
Latest events from The India Cements
- Sales and EBITDA improved as expansion, brand transition, and restructuring progressed.INDIACEM
Q2 25/263 Feb 2026 - Sales up 25% YoY, revenue higher, but net losses persist amid expansion and legal risks.INDIACEM
Q3 25/262 Feb 2026 - Profitability returned in Q1 FY25 on an exceptional gain, with major stake sale to UltraTech Cement.INDIACEM
Q1 24/251 Sep 2025 - Losses widened on lower revenue, with major asset sales and a pending UltraTech acquisition.INDIACEM
Q2 24/251 Sep 2025 - Q3 FY25 saw lower revenue, major losses, UltraTech's takeover, and large asset revaluation gains.INDIACEM
Q3 24/251 Sep 2025 - FY25 saw deeper losses, lower revenue, and major legal disputes, with auditors' unmodified opinions.INDIACEM
Q4 24/251 Sep 2025